hrcak mascot   Srce   HID

Pregledni rad

The side effects of new oral anticoagulants

Alma Starčević ; Klinički zavod za transfuzijsku medicinu, KBC Rijeka, Rijeka
Nada Vukelić-Damijani ; Klinički zavod za transfuzijsku medicinu, KBC Rijeka, Rijeka
Sanja Balen ; Klinički zavod za transfuzijsku medicinu, KBC Rijeka, Rijeka
Vera Vlahović-Palčevski ; Odjel za kliničku farmakologiju, KBC Rijeka, Rijeka

Puni tekst: hrvatski, pdf (629 KB) str. 267-275 preuzimanja: 3.835* citiraj
APA 6th Edition
Starčević, A., Vukelić-Damijani, N., Balen, S. i Vlahović-Palčevski, V. (2015). Nuspojave oralnih antikoagulantnih lijekova. Medicina Fluminensis, 51 (2), 267-275. Preuzeto s https://hrcak.srce.hr/139472
MLA 8th Edition
Starčević, Alma, et al. "Nuspojave oralnih antikoagulantnih lijekova." Medicina Fluminensis, vol. 51, br. 2, 2015, str. 267-275. https://hrcak.srce.hr/139472. Citirano 22.10.2021.
Chicago 17th Edition
Starčević, Alma, Nada Vukelić-Damijani, Sanja Balen i Vera Vlahović-Palčevski. "Nuspojave oralnih antikoagulantnih lijekova." Medicina Fluminensis 51, br. 2 (2015): 267-275. https://hrcak.srce.hr/139472
Harvard
Starčević, A., et al. (2015). 'Nuspojave oralnih antikoagulantnih lijekova', Medicina Fluminensis, 51(2), str. 267-275. Preuzeto s: https://hrcak.srce.hr/139472 (Datum pristupa: 22.10.2021.)
Vancouver
Starčević A, Vukelić-Damijani N, Balen S, Vlahović-Palčevski V. Nuspojave oralnih antikoagulantnih lijekova. Medicina Fluminensis [Internet]. 2015 [pristupljeno 22.10.2021.];51(2):267-275. Dostupno na: https://hrcak.srce.hr/139472
IEEE
A. Starčević, N. Vukelić-Damijani, S. Balen i V. Vlahović-Palčevski, "Nuspojave oralnih antikoagulantnih lijekova", Medicina Fluminensis, vol.51, br. 2, str. 267-275, 2015. [Online]. Dostupno na: https://hrcak.srce.hr/139472. [Citirano: 22.10.2021.]

Sažetak
New oral anticoagulants (NOACs), direct thrombin inhibitor (dabigatran etexilat) and factor Xa inhibitors (rivaroxaban and apixaban) both show noninferiority or even superiority to warfarin in the prevention or treatment of venous thromboembolism. This brief review describes the mechanism of action, clinical use and side effects of new oral anticoagulants. Like all other anticoagulant drugs, the NOACs carry an increased risk of bleeding. Unlike warfarin, the NOACs represent a clinical challenge due to the lack of specific antidotes and tests for the measurement of drug levels. When choosing anticoagulant therapy, the
physician must apply a personalized approach to each patient.

Ključne riječi
apixaban; dabigatran etexilat; rivaroxaban; side effects

Hrčak ID: 139472

URI
https://hrcak.srce.hr/139472

[hrvatski]

Posjeta: 4.360 *